Investigation of benzimidazole anthelmintics as oral anticancer agentsopen access
- Authors
- Jang, J[Jang, Jiyoon]; Lee, K[Lee, Kwangho]; Koh, B[Koh, Byumseok]
- Issue Date
- May-2022
- Publisher
- WILEY-V C H VERLAG GMBH
- Keywords
- anthelmintic; cancer; fenbendazole; microtubule inhibitor; oral drug; oxibendazole
- Citation
- BULLETIN OF THE KOREAN CHEMICAL SOCIETY, v.43, no.5, pp.750 - 756
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Volume
- 43
- Number
- 5
- Start Page
- 750
- End Page
- 756
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/96423
- DOI
- 10.1002/bkcs.12519
- ISSN
- 0253-2964
- Abstract
- Recently, there has been social controversy regarding whether benzimidazole anthelmintic drugs can be used as anticancer drugs. On this note, we wish to address the use of current benzimidazole anthelmintic drugs for the treatment of cancer patients. We explored the anticancer efficacy of benzimidazole anthelmintic drugs in vitro and their mechanism of action. We also conducted pharmacokinetic studies of two benzimidazole anthelmintics and assessed the predictive systemic efficacy. Finally, we present the anticancer efficacy of benzimidazole anthelmintics' putative metabolites from hydrolysis. Our data suggest that benzimidazole anthelmintic drugs are not expected to show systemic anticancer efficacy in vivo due to poor pharmacokinetic parameters. Therefore, patients should not consider oxibendazole or fenbendazole as cancer treatment option.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/96423)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.